These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33284384)

  • 41. Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids.
    You-Ning L; Humphries M; Du X; Wang L; Jiang J
    Int J Clin Pract; 2005 Jul; 59(7):754-9. PubMed ID: 15963199
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma.
    Bateman ED; Silins V; Bogolubov M
    Respir Med; 2001 Feb; 95(2):136-46. PubMed ID: 11217910
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma.
    O'Connor RD; Nelson H; Borker R; Emmett A; Jhingran P; Rickard K; Dorinsky P
    Pharmacoeconomics; 2004; 22(12):815-25. PubMed ID: 15294013
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
    Pearlman DS; Stricker W; Weinstein S; Gross G; Chervinsky P; Woodring A; Prillaman B; Shah T
    Ann Allergy Asthma Immunol; 1999 Mar; 82(3):257-65. PubMed ID: 10094216
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Ferguson GT; Anzueto A; Fei R; Emmett A; Knobil K; Kalberg C
    Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Maintenance asthma treatment with fluticasone/salmeterol combination via Diskus: effect on outcomes in inner-city children enrolled in TennCare.
    Nguyen WT; Stewart C; Fisher K; Tolley E; Lew DB; Self TH
    Allergy Asthma Proc; 2005; 26(2):129-34. PubMed ID: 15971472
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
    Beeh KM; Derom E; Echave-Sustaeta J; Grönke L; Hamilton A; Zhai D; Bjermer L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():193-205. PubMed ID: 26893551
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of inhaled salmeterol/fluticasone propionate combination product versus budesonide on the health-related quality of life of patients with asthma.
    Juniper EF; Jenkins C; Price MJ; James MH
    Am J Respir Med; 2002; 1(6):435-40. PubMed ID: 14720030
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of patient-reported outcomes during treatment with adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler versus fixed-dose fluticasone propionate/salmeterol dry powder inhaler in patients with asthma.
    O'Connor RD; Patrick DL; Parasuraman B; Martin P; Goldman M
    J Asthma; 2010 Mar; 47(2):217-23. PubMed ID: 20170333
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Dose-Response Study to Examine the Methodology for Demonstrating the Local Therapeutic Equivalence of the Fluticasone Propionate Component of an Orally Inhaled Combination Therapy of Fluticasone Propionate/Salmeterol Dry Powder.
    Allan R; Haughie S; Kerwin E; Ward J
    J Aerosol Med Pulm Drug Deliv; 2019 Dec; 32(6):364-373. PubMed ID: 31259655
    [No Abstract]   [Full Text] [Related]  

  • 51. Comparison table: Inhaled long-acting bronchodilators for treatment of COPD.
    Med Lett Drugs Ther; 2020 Sep; 62(1606):e146-e147. PubMed ID: 32960874
    [No Abstract]   [Full Text] [Related]  

  • 52. [Efficacy and safety of salmeterol (50 microgram) and fluticasone (250 microgram) in a single inhaler device (diskus) in patients with mild to moderate asthma].
    Beeh KM; Beier J; Kornmann O; Wiewrodt R; Buhl R;
    Pneumologie; 2002 Feb; 56(2):91-7. PubMed ID: 11842346
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-effectiveness of Advair: fluticasone propionate and salmeterol combination.
    Tano B; Pathak D; Hoffmann S
    Expert Rev Pharmacoecon Outcomes Res; 2003 Dec; 3(6):741-7. PubMed ID: 19807351
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline.
    Dal Negro RW; Pomari C; Tognella S; Micheletto C
    Pulm Pharmacol Ther; 2003; 16(4):241-6. PubMed ID: 12850128
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD.
    Schermer TR; Albers JM; Verblackt HW; Costongs RJ; Westers P
    Fam Pract; 2007 Apr; 24(2):181-8. PubMed ID: 17251178
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD.
    Donohue JF; Kalberg C; Emmett A; Merchant K; Knobil K
    Treat Respir Med; 2004; 3(3):173-81. PubMed ID: 15219176
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978].
    Sin DD; Man SF; Marciniuk DD; Ford G; FitzGerald M; Wong E; York E; Mainra RR; Ramesh W; Melenka LS; Wilde E; Cowie RL; Williams D; Rousseau R;
    BMC Pulm Med; 2006 Feb; 6():3. PubMed ID: 16460562
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone.
    Fowler SJ; Currie GP; Lipworth BJ
    J Allergy Clin Immunol; 2002 Jun; 109(6):929-35. PubMed ID: 12063520
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Steroid-sparing effects of fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 microg administered twice daily.
    Busse W; Koenig SM; Oppenheimer J; Sahn SA; Yancey SW; Reilly D; Edwards LD; Dorinsky PM
    J Allergy Clin Immunol; 2003 Jan; 111(1):57-65. PubMed ID: 12532097
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness and Treatment Compliance of Salmeterol-Fluticasone Easyhaler
    Tamási L; Bartha A; Ferencz A; Tímár M; Vahteristo M; Takala A; Müller V
    Pulm Ther; 2022 Dec; 8(4):369-384. PubMed ID: 36318368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.